Characterization of the effect of in vivo doxorubicin treatment on skeletal muscle function in the rat

Anticancer Research

Volumn 31, Issue 6, 2011, Pages 2023-2028

  Hydock, David S ^a   Lien, Chia Ying ^a   Jensen, Brock T ^a   Schneider, Carole M ^a   Hayward, Reid ^a  

^a UNIVERSITY OF NORTHERN COLORADO   (United States)

Author keywords

Adriamycin; Cardiotoxicity; Fatigue; Myotoxicity

Indexed keywords

DOXORUBICIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; EXTENSOR DIGITORUM LONGUS MUSCLE; HEART DISEASE; HEART FUNCTION; IN VIVO STUDY; MALE; MUSCLE FATIGUE; MUSCLE FUNCTION; NONHUMAN; PRIORITY JOURNAL; RAT; SKELETAL MUSCLE; SOLEUS MUSCLE; TRANSTHORACIC ECHOCARDIOGRAPHY;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BODY WEIGHT; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; MALE; MUSCLE CONTRACTION; MUSCLE STRENGTH; MUSCLE, SKELETAL; RATS; RATS, SPRAGUE-DAWLEY;

EID: 79960438429     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Fairclough DL, Fetting JH, Cella D, Wonson W and Moinpour CM: Quality of life and quality-adjusted survival for breast cancer patients receiving adjuvant therapy. Eastern Cooperative Oncology Group (ECOG). Qual Life Res 8: 723-731, 1999. (Pubitemid 30331120)
2. Liu J, Tu D, Dancey J, Reyno L, Pritchard KI, Pater J and Seymour LK: Quality of life analyses in a clinical trial of DPPE (tesmilifene) plus doxorubicin versus doxorubicin in patients with advanced or metastatic breast cancer: NCIC CTG Trial MA.19. Breast Cancer Res Treat 100: 263-271, 2006.
3. Lipshultz SE, Lipsitz SR, Sallan SE, Dalton VM, Mone SM, Gelber RD and Colan SD: Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. J Clin Oncol 23: 2629-2636, 2005. (Pubitemid 46179451)
4. Belham M, Kruger A, Mepham S, Faganello G and Pritchard C: Monitoring left ventricular function in adults receiving anthracycline-containing chemotherapy. Eur J Heart Fail 9: 409-414, 2007. (Pubitemid 46441967)
5. Wallace KB: Doxorubicin-induced cardiac mitochondrionopathy. Pharmacol Toxicol 93: 105-115, 2003.
6. Wallace KB: Adriamycin-induced interference with cardiac mitochondrial calcium homeostasis. Cardiovasc Toxicol 7: 101-107, 2007.
7. Ito H, Miller SC, Billingham ME, Akimoto H, Torti SV, Wade R, Gahlmann R, Lyons G, Kedes L and Torti FM: Doxorubicin selectively inhibits muscle gene expression in cardiac muscle cells in vivo and in vitro. Proc Natl Acad Sci USA 87: 4275-4279, 1990.
8. Abramson JJ, Buck E, Salama G, Casida JE and Pessah IN: Mechanism of anthraquinone-induced calcium release from skeletal muscle sarcoplasmic reticulum. J Biol Chem 263: 18750-18758, 1988. (Pubitemid 19016332)
9. Zorzato F, Salviati G, Facchinetti T and Volpe P: Doxorubicin induces calcium release from terminal cisternae of skeletal muscle. A study on isolated sarcoplasmic reticulum and chemically skinned fibers. J Biol Chem 260: 7349-7355, 1985. (Pubitemid 15059376)
10. De Beer EL, Finkle H, Voest EE, Van Heijst BG and Schiereck P: Doxorubicin interacts directly with skinned single skeletal muscle fibres. Eur J Pharmacol 214: 97-100, 1992.
11. van Norren K, van Helvoort A, Argiles JM, van Tuijl S, Arts K, Gorselink M, Laviano A, Kegler D, Haagsman HP and van der Beek EM: Direct effects of doxorubicin on skeletal muscle contribute to fatigue. Br J Cancer 100: 311-314, 2009.
12. Neilan TG, Jassal DS, Perez-Sanz TM, Raher MJ, Pradhan AD, Buys ES, Ichinose F, Bayne DB, Halpern EF, Weyman AE, Derumeaux G, Bloch KD, Picard MH and Scherrer-Crosbie M: Tissue Doppler imaging predicts left ventricular dysfunction and mortality in a murine model of cardiac injury. Eur Heart J 27: 1868-1875, 2006.
13. Nousiainen T, Jantunen E, Vanninen E and Hartikainen J: Early decline in left ventricular ejection fraction predicts doxorubicin cardiotoxicity in lymphoma patients. Br J Cancer 86: 1697-1700, 2002. (Pubitemid 34712910)
14. Dalla Libera L, Vescovo G and Volterrani M: Physiological basis for contractile dysfunction in heart failure. Curr Pharm Des 14: 2572-2581, 2008.
15. Celik T, Iyisoy A, Celik M, Yuksel UC and Isik E: Muscle wastage in heart failure: orphan of the heart failure. Int J Cardiol 135: 233-236, 2009.
16. van Hees HW, van der Heijden HF, Ottenheijm CA, Heunks LM, Pigmans CJ, Verheugt FW, Brouwer RM and Dekhuijzen PN: Diaphragm single-fiber weakness and loss of myosin in congestive heart failure rats. Am J Physiol Heart Circ Physiol 293: H819-828, 2007.
17. Harrington D, Anker SD, Chua TP, Webb-Peploe KM, Ponikowski PP, Poole-Wilson PA and Coats AJ: Skeletal muscle function and its relation to exercise tolerance in chronic heart failure. J Am Coll Cardiol 30: 1758-1764, 1997. (Pubitemid 27521259)
18. Smuder AJ, Kavazis AN, Min K and Powers SK: Exercise protects against doxorubicin-induced oxidative stress and proteolysis in skeletal muscle. J Appl Physiol 110: 934-942, 2011.
19. Gilliam LA, Ferreira LF, Breton JD, Moylan JS, Westerblad H, St Clair DK and Reid MB: Doxorubicin acts through tumor necrosis factor receptor subtype 1 to cause dysfunction of murine skeletal muscle. J Appl Physiol 107: 1935-1942, 2009.
20. Gilliam LA, Moylan JS, Ann Callahan L, Sumandea MP and Reid MB: Doxorubicin causes diaphragm weakness in murine models of cancer chemotherapy. Muscle Nerve 43: 94-102.
21. Hayward R and Hydock DS: Doxorubicin cardiotoxicity in the rat: an in vivo characterization. J Am Assoc Lab Anim Sci 46: 20-32, 2007.
22. Rose AJ, Alsted TJ, Jensen TE, Kobbero JB, Maarbjerg SJ, Jensen J and Richter EA: A Ca(2+)- calmodulin-eEF2K-eEF2 signalling cascade, but not AMPK, contributes to the suppression of skeletal muscle protein synthesis during contractions. J Physiol 587: 1547-1563, 2009.
23. Aslesen R, Engebretsen EM, Franch J and Jensen J: Glucose uptake and metabolic stress in rat muscles stimulated electrically with different protocols. J Appl Physiol 91: 1237-1244, 2001. (Pubitemid 32803918)
24. Stathopoulos GP, Papadopoulos NG, Stephanopoulou A, Dontas I, Kotsarelis D and Karayannacos PE: An increase of serum lipids after cumulative doses of doxorubicin and epirubicin in experimental animals. Anticancer Res 16: 3429-3433, 1996. (Pubitemid 27084993)
25. Harrington D and Coats AJ: Skeletal muscle abnormalities and evidence for their role in symptom generation in chronic heart failure. Eur Heart J 18: 1865-1872, 1997.
26. Ertunc M, Sara Y and Onur R: Differential contractile impairment of fast- and slow-twitch skeletal muscles in a rat model of doxorubicin-induced congestive heart failure. Pharmacology 84: 240-248, 2009.
27. Cusack BJ, Gambliel H, Musser B, Hadjokas N, Shadle SE, Charlier H and Olson RD: Prevention of chronic anthracycline cardiotoxicity in the adult Fischer 344 rat by dexrazoxane and effects on iron metabolism. Cancer Chemother Pharmacol 58: 517-526, 2006.
28. Cusack BJ, Musser B, Gambliel H, Hadjokas NE and Olson RD: Effect of dexrazoxane on doxorubicin pharmacokinetics in young and old rats. Cancer Chemother Pharmacol 51: 139-146, 2003. (Pubitemid 36259474)
29. Riad A, Bien S, Westermann D, Becher PM, Loya K, Landmesser U, Kroemer HK, Schultheiss HP and Tschope C: Pretreatment with statin attenuates the cardiotoxicity of doxorubicin in mice. Cancer Res 69: 695-699, 2009.
30. Hydock DS, Lien CY and Hayward R: Anandamide preserves cardiac function and geometry in an acute doxorubicin cardiotoxicity rat model. J Cardiovasc Pharmacol Ther 14: 59-67, 2009.
31. Berthiaume JM, Oliveira PJ, Fariss MW and Wallace KB: Dietary vitamin E decreases doxorubicin- induced oxidative stress without preventing mitochondrial dysfunction. Cardiovasc Toxicol 5: 257-267, 2005. (Pubitemid 41506867)
32. Chao HH, Liu JC, Hong HJ, Lin JW, Chen CH and Cheng TH: L-Carnitine reduces doxorubicin- induced apoptosis through a prostacyclin-mediated pathway in neonatal rat cardiomyocytes. Int J Cardiol 146: 145-152, 2009.
33. Tesoriere L, Ciaccio M, Valenza M, Bongiorno A, Maresi E, Albiero R and Livrea MA: Effect of vitamin A administration on resistance of rat heart against doxorubicin-induced cardiotoxicity and lethality. J Pharmacol Exp Ther 269: 430-436, 1994. (Pubitemid 24143284)
34. Todorova VK, Kaufmann Y, Hennings L and Klimberg VS: Oral glutamine protects against acute doxorubicin-induced cardiotoxicity of tumor-bearing rats. J Nutr 140: 44-48, 2009.
35. Chicco AJ, Hydock DS, Schneider CM and Hayward R: Low-intensity exercise training during doxorubicin treatment protects against cardiotoxicity. J Appl Physiol 100: 519-527, 2006. (Pubitemid 43671603)
36. Chicco AJ, Schneider CM and Hayward R: Voluntary exercise protects against acute doxorubicin cardiotoxicity in the isolated perfused rat heart. Am J Physiol Regul Integr Comp Physiol 289: R424-R431, 2005. (Pubitemid 41060497)
37. Chicco AJ, Schneider CM and Hayward R: Exercise training attenuates acute doxorubicin-induced cardiac dysfunction. J Cardiovasc Pharmacol 47: 182-189, 2006. (Pubitemid 44384055)
38. Hydock DS, Lien CY, Schneider CM and Hayward R: Exercise preconditioning protects against doxorubicin-induced cardiac dysfunction. Med Sci Sports Exerc 40: 808-817, 2008.
39. Hydock DS, Wonders KY, Schneider CM and Hayward R: Voluntary wheel running in rats receiving doxorubicin: effects on running activity and cardiac myosin heavy chain. Anticancer Res 29: 4401-4407, 2009.